Pharmicell Co (A005690) Q2 2025 earnings summary

Executive summary

• Operates two main divisions: Bio-Medical (stem cell therapies, storage, cosmetics) and Bio-Chemical (pharmaceutical intermediates, specialty chemicals).

• No subsidiaries or affiliates as of the reporting date.

• Major R&D focus on stem cell therapies for liver cirrhosis, erectile dysfunction, and chronic kidney disease, with multiple clinical trials ongoing.

• Completed construction of new GMP and chemical plants to expand production capacity.

Financial highlights

• Revenue for H1 2025: KRW 53,792 million, down from KRW 64,851 million in FY2024.

• Operating income for H1 2025: KRW 16,545 million, up from KRW 7,133 million in FY2024.

• Net income for H1 2025: KRW 15,841 million, up from KRW 6,331 million in FY2024.

• Cash and cash equivalents increased to KRW 70,928 million as of June 2025.

• Gross margin improved year-over-year.

Outlook and guidance

• Continued investment in R&D and expansion of clinical trials for new stem cell therapies.

• Ongoing construction of Ulsan Plant 3 to meet anticipated demand for advanced materials and pharmaceutical ingredients.

• Focus on expanding domestic and international sales, especially in the Bio-Chemical segment.